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Abstract
Langerhans cells (LC) represent a well characterized subset of dendritic cells located in the epidermis of skin and mucosae.
In vivo, they originate from resident and blood-borne precursors in the presence of keratinocyte-derived TGFb. In vitro, LC
can be generated from monocytes in the presence of GM-CSF, IL-4 and TGFb. However, the signals that induce LC during an
inflammatory reaction are not fully investigated. Here we report that Activin A, a TGFb family member induced by pro-
inflammatory cytokines and involved in skin morphogenesis and wound healing, induces the differentiation of human
monocytes into LC in the absence of TGFb. Activin A-induced LC are Langerin
+, Birbeck granules
+, E-cadherin
+, CLA
+ and
CCR6
+ and possess typical APC functions. In human skin explants, intradermal injection of Activin A increased the number of
CD1a
+ and Langerin
+ cells in both the epidermis and dermis by promoting the differentiation of resident precursor cells.
High levels of Activin A were present in the upper epidermal layers and in the dermis of Lichen Planus biopsies in
association with a marked infiltration of CD1a
+ and Langerin
+ cells. This study reports that Activin A induces the
differentiation of circulating CD14
+ cells into LC. Since Activin A is abundantly produced during inflammatory conditions
which are also characterized by increased numbers of LC, we propose that this cytokine represents a new pathway,
alternative to TGFb, responsible for LC differentiation during inflammatory/autoimmune conditions.
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Introduction
Langerhans cells (LC) are specialized dendritic cells (DC)
normally found in the epidermis and mucosal stratified epithelia
[1–5]. Contrary to myeloid and plasmacytoid DC, LC express the
C-type lectin CD207 (Langerin), the major constituent of Birbeck
granules, which represent the hallmark of LC [6–8]. LC also
express a characteristic set of cell-surface molecules, such as
cutaneous lymphocyte-associated antigen (CLA), E-cadherin and
the CC chemokine receptor 6 (CCR6) [9–13]. As immature cells,
their primary function is to sense the environment for danger
signals and capture antigens; then LC undergo a process of
functional and phenotypic maturation and migrate to the regional
lymph nodes [5; 10; 14; 15].
Several evidences suggest that LC are of myeloid origin and can
differentiate from monocytes or CD34
+ precursors [16–20]. While
the generation of DC from monocytes requires GM-CSF and IL-4
only, the additional presence of TGFb1 in the cytokine milieu
appears to be essential for the development of LC [17; 18].
Accordingly, TGFb1-deficient mice display a severe defect in LC,
but not in DC, development [21]. IL-15 is the only other cytokine
known until now to skew monocyte differentiation toward LC-type
DC; though, IL-15-derived LC are Langerin
+ but lack Birbeck
granules [22].
According to the current model of LC differentiation, in steady-
state conditions LC are maintained locally by a stable renewable
populationpresentintheskin[23–25].Theexistenceofskin-resident
LC precursors was postulated by Lareggina et al who described
dermalCD14
+cellsthatexpressLangerinandCCR6andareableto
acquire LC features when cultured in the presence of TGFb1 [26].
When the skin is exposed to inflammatory stimuli (UV rays,
infections, allergens) LC increase their expression of class II MHC
and costimulatory molecules and migrate to regional lymph nodes.
In this situation of accelerated turnover, LC are replaced by blood-
borne precursors such as inflammatory Gr-1
+ monocytes recruited
through a CCR2-dependent mechanism [23; 27; 28].
The epidermal environment can contribute to the attraction of
precursors and to their differentiation into LC. Keratinocyte
production of MIP-3a/CCL20 and TGF may direct CCR6
+ LC
precursors to the epidermis and induce their entry into the LC
pathway, respectively [9; 18; 21]. However, LC differentiation could
alsodepend onthedermalcytokineenvironmentonceLCprecursors
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3271have entered the skin to colonize the dermis, or are trafficking
through the dermis to the overlying epidermis. Indeed, emerging
evidence support the concept that in certain skin pathological
conditions a conspicuous expansion of the LC population occurs
within the dermis [29–32] suggesting, that LC differentiation factors
might also be produced within the dermal compartment.
Activin A is a member of the TGFb1 family initially identified
for its ability to control the secretion of follicle-stimulating
hormone. Activin A is presently also known for its activity on
growth and differentiation of various cell types during organogen-
esis, and for its role in wound healing, inflammation and tumor
progression [33–36]. Activin A binds to specific transmembrane
serine/threonine kinase receptors (ActRIB and ActRII) and to
follistatin, a secreted protein that inhibits protein functions by
sequestration [37–39]. Activin A is strongly induced after skin
injury, probably by serum growth factors released upon haemor-
rhage and by macrophage-derived pro-inflammatory cytokines
[40; 41]. Transgenic mice overexpressing Activin A in the
epidermis show strong hyperthickened epidermis, accelerated
wound healing and enhanced scarring [42; 43]. Conversely, in
transgenic mice overexpressing the antagonist follistatin, skin
wound closure is delayed and scar formation reduced [44].
Curiously, LC are strongly reduced in the skin of follistatin
transgenic mice, suggesting a role of Activin A in LC biology [45].
This study shows that Activin A induces the differentiation of
LC in vitro and ex-vivo and candidates Activin A as a new
differentiation pathway that might be relevant in conditions
characterized by the local production of Activin A and
accumulation of LC.
Results
Activin A induces the differentiation of circulating
monocytes into DC with phenotypic and ultrastructural
features of LC
Highlypurified monocyteswereculturedfor6dayswithActivinA
inthepresenceof GM-CSFandIL-4, twocytokinesthatwereshown
to cooperate with TGFb1 in the differentiation of monocytes to LC
[16;18].Thesecells(thereaftercalledAct A-LCtodifferentiate them
from TGFb1-LC) were CD14
2 and expressed typical LC markers,
such as CD1a, Langerin, E-caderin, CLA and CCR6. At day 6, Act
A-LC presented an immature phenotype with a modest expression
of CD80, CCR7 and CD83 (Fig. 1A). The presence of Birbeck
granules, the hallmark of epidermal LC [7] was assessed by
transmission electron microscopy on ultrathin-sections of Act A-
LC cells (Fig. 1B). These cells displayed dendritic morphology with
slightly off centred indented nuclei. The cytoplasm contained
Birbeck granules, cytoplasmic organelles with rod like profile,
electron-opaque central lamella and rounded ends. More open-
ended tennis-racket shaped granules were also observed. Taken
together this set of data indicates that Activin A, in the presence of
GM-CSF and IL-4, induces the differentiation of circulating
monocytes into LC. The possibility that the effect of Activin A
could be due to the secondary induction of TGFb, was investigated
by real-time PCR. As shown in Figure 1C, TGFb1m R N Aw a s
barely detectable in Act A-LC cultures and similar results were
obtained for TGFb2 and TGFb3 (data not shown); TGFb1w a sa l s o
weakly induced in TGFb1-LC. On the contrary, Activin A mRNA
was strongly upregulated by both Activin A and TGFb1, suggesting
the existence of an amplificatory loop. In agreement with mRNA
levels, TGFb1 concentration was below the detection limits
(sensitivity 4.61 pg/ml) in Act A-LC supernatants, whereas Activin
A was induced at 1.05 ng/10
6 cells (n=5, n=6) in TGFb1-LC.
Furthermore, Act A-LC generation was not blocked by the addition
of anti-TGFb1 (data not shown), supporting a TGFb1-independent
differentiation of Act A-LC. Finally, it was tested whether bone
morphogenetic protein (BMP-6), another TGF family member
protein, could also induce LC differentiation. Figure 1D shows that
BMP-6 did notsustain phenotypicLCdifferentiation, indicating that
the abilityto induceLCdifferentiationisnot ageneralfeature shared
by all TGFb family member proteins.
Phenotypical and functional characterization of Act A-LC
Membrane phenotype and functions were tested in immature and
CD40L-mature Act A-LC. As shown in Figure 2A CD40L-activated
Act A-LC showed increased surface expression of CD80 and CD83
as well as the expression of CXCR4 and CCR7, two maturation-
associated chemokine receptors; these data are consistent with the
acquisition of a mature phenotype. Immature Act A-LC efficiently
stimulated T cell proliferation and their allostimulatory capacity was
further enhanced upon maturation (Fig. 2B). In agreement with the
expression of CCR6 (Fig. 1A and data not shown), immature, but
not mature Act A-LC migrated in response to CCL20 (Fig. 2C). On
the contrary, CD40L-mature cells migrated in response to CCL19,
one ofthe CCR7ligands(data not shown).Finally,CD40L-activated
Act A-DC secreted IL-12p70, TNF, CCL22 and CCL20 in a similar
manner to TGFb1-LC, with the exception of IL-12 which was
consistently produced at higher levels by Act A-LC (Fig. 2D).
Therefore, LC generated in the presence of Activin A have the
capacity to undergo a full maturation process based on membrane
phenotype, migration and functional properties.
Activin A induces the generation of Langerin
+ cells ex-
vivo in human skin explants
To investigate the ability of Activin A to induce LC differentiation
within the skin milieu, skin explants were intradermally injected with
Activin A and subsequently cultured in six-well culture plates at the
air-medium interface with the epidermis side up [46]. Explants were
subsequently removed and examined by immunohistochemistry. As
expected, fresh, untreated skin explants revealed several Langerin
+
cells within the epidermis (Fig. 3) and a similar picture was observed
following the injection of medium. Instead, the inoculation of100 ng
ActivinA led toaprofoundincreaseinthenumberofLangerin
+cells
both in the epidermis and in the dermal layer, with a maximal
induction observed 72 hrs after the injection. The increase of the
number of Langerin
+ cells was of about 2-fold and 10-fold (n=6) in
the epidermis and dermis, respectively, and was statistically
significant with respect to control skin (p,0.05, by Student’s t-test;
Fig. 3). The number of CD1a
+ cells also increased in parallel to
Langerin expression (data not shown). These results show that
Activin A is able to induce the differentiation of LC precursors
resident within normal skin.
Activin A promotes LC differentiation from precursors
cells present in the dermal layer
To exclude that the increased number of LC observed in the
dermis following Activin A injection could be due to migration of
LC from the epidermis, the dermis was separated by dispase
digestion and thereafter injected with Activin A. Also under these
experimental conditions, Activin A inoculation strongly increased
the number of Langerin
+ cells (Fig. 4). To better address the
potential of dermal precursors to differentiate into LC under the
influence of Activin A, skin migratory cells were recovered from
dermal layers and subsequently cultured in the presence of Activin
A. At day 6 of culture, a consistent number of cells, 15% and 20%
were positive for CD1a and Langerin, respectively. Conversely, no
Langerin
+ cells could be detected in the absence of Activin A.
Activin A & LC Differentiation
PLoS ONE | www.plosone.org 2 September 2008 | Volume 3 | Issue 9 | e3271Figure 1. Activin A promotes Langerhans cell differentiation from human CD14
+ monocytes. (A) Phenotypic analysis of monocytes
cultured for 6 days with GM-CSF and IL-4 in the presence of Activin A (Act A-LC) or TGFb1 (TGFb1-LC). Cells were stained with the indicated moAbs
(filled histograms) or isotype-matched negative control moAbs (open histograms). Percentages of positive cells are shown in the upper right corner
of each histogram. The figure shows one experiment representative of at least five independent cultures. (B) Electron microscopy analysis of Act A-
LC. Act A-LC exhibited abundant dendritic membrane protrusions and lobulated or indented nuclei (left panel, 3,000X, bar 40 mm). Cytoplasm
presented a rough endoplasmic reticulum, many multilamellar organelles and numerous electron-dense structures reminiscent of Birbeck granules
(right panel, 12,000X, bar 1 mm). The inset shows rod-shaped Birbeck granules (200,000X, bar 20 mm). (C) TGFb1 and Activin A mRNA expression in
Act A-LC and TGFb1-LC cultures. Monocytes were cultured in the presence of Act A or TGFb1 for the indicated time and the expression of TGFb1 and
Activin A mRNA was determined by real-time PCR, relative to GAPDH mRNA used as internal control. The expression level in freshly isolated
monocytes was assumed as the 1.0 value. Similar results were obtained in three different donors. (D) Effects of different TGF family members on LC
differentiation. Monocytes were cultured for 6 days with GM-CSF in the presence of 10 ng/ml TGFb1, 100 ng/ml Activin A, or 100 ng/ml BMP6 and
analyzed for Langerin, E-caderin and CCR6 expression by flow cytometry analysis. Data are representative of at least four independent cultures.
doi:10.1371/journal.pone.0003271.g001
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PLoS ONE | www.plosone.org 3 September 2008 | Volume 3 | Issue 9 | e3271Figure 2. Phenotypical and functional characterization of CD40L-activated Act A-LC (A) Expression of maturation markers by Act A-LC.
Act A-LC were incubated with CD40L-transfected fibroblasts for 40 hrs and stained with anti-CD80, CD83, CCR7 and CXCR4 moAbs (filled histograms)
or isotype-matched negative control Abs (open histograms). Results obtained with TGFb1-LC are also shown for comparison. The percentage of
positive cells is reported in each panel. Data shown are representative of three independent experiments. (B) Allostimulatory capacity of Act A-LC.
Irradiated immature or CD40L-matured Act A-LC (or TGFb1-LC) were cultured with 2610
5 allogeneic purified T cells. Proliferation was assayed as
uptake of [H
3]thymidine added in the last 16 hrs of a 6-day culture assay. Results are expressed as mean counts per minute (cpm)6SD of one
representative experiment performed in triplicate. Values are at the net of T cell proliferation in the absence of DC (32506250 cpm). (C) Act A-LC
migrate in response to CCL20. Immature or CD40L-mature Act A-LC or TGFb1-LC were applied to the upper wells of the chemotaxis chamber. CCL20
was added to the lower level of the chamber. The number of cells migrated to the lower chamber was counted. Each assay was performed in
triplicate and the results are expressed as the mean6SD number of migrated cells (representative of three experiments). (D) Cytokine release by Act
A-LC. Immature or CD40L-mature Act A-LC or TGFb1-LC were assessed for their ability to release the indicated cytokines by ELISA. Results are the
average determination (6SD) of four independent experiments.
doi:10.1371/journal.pone.0003271.g002
Activin A & LC Differentiation
PLoS ONE | www.plosone.org 4 September 2008 | Volume 3 | Issue 9 | e3271Altogether, these data show that skin precursors, present within
the dermis, can be induced to differentiate into LC by Activin A.
Dermal accumulation of Langerhans cells in lichen planus
is associated with abundant production of Activin A
Although LC are predominantly confined to the epidermis, we
and others have recently documented that in certain pathological
conditions, such as lichen planus, LC are also abundantly found in
the stromal compartment [29; 30; 32]. As shown in Fig. 5 (panel a),
in normal skin and mucosa LC are regularly distributed within the
epithelium in the basal and suprabasal layers and are easily
recognized based on their dendritic morphology and expression of
Langerin [7]. On the contrary, in the large majority of the lichen
planus cases investigated (32/34) variable numbers of Langerin
+
dendritic cells were identifiable in the stromal compartment (Fig. 5,
panel b), distributed as sparse cells or clusters within the
mononuclear infiltrate (Fig. 5, panel c). Of interest, many of these
Langerin
+ cells were detected in close proximity to blood vessels, as
shown by double immunofluorescence for Langerin and Factor
VIII-related antigen (Fig. 5, panel c, inset). In normal skin a weak
reactivity for Activin A was detected in epidermal keratinocytes and
rare spindle cells (likely representing dermal macrophages or
dendritic cells); a stronger positivity was also observed in scattered
mast cell [47] (Fig. 5, panel d). Compared to normal skin, lesional
skin and mucosa from lichen planus biopsies showed strong
induction of Activin A in the upper layers of the epidermis and,
particularly,inthe stromal compartment (Figure 5,panelpanele).In
the latter, Activin A was mostly produced by non-lymphoid
mononuclear cells, endothelial cells and mast cells (Figure 5, panel f)
Discussion
This study reports that Activin A, a protein abundantly
produced in the skin during normal and pathological wound
healing [40; 47] and inflammatory/autoimmune diseases (this
study), induces the differentiation of human CD14
+ monocytes in
Langerin
+, Birbeck granules
+, E-cadherin
+, CLA
+ and CCR6
+
cells. LC originate in vitro from CD34
+ bone marrow precursors
[16; 17; 19; 20]. Monocytes also represent LC blood precursor
cells in vitro and in vivo [18; 22; 27; 28]. Indeed, CD14
+ cells can
be induced to differentiate into LC by a cytokine combination
including GM-CSF, IL-4 and TGFb1 [18]. The crucial role of
Figure 3. Intradermal injection of Activin A induces the differentiation of dermal and epidermal Langerhans cells in human skin
explants. Langerin expression was evaluated in the epidermis and dermis (full thickness skin explants) of skin explants, untreated and 72 hrs after i.d.
injection of medium or 100 ng Activin A (magnification 100X, inset 400X) The number of Langerin
+ cells were quantified in skin explants by
evaluating six different skin sections (0.05 mm
2/field; means6SD). * p,0.05 by Student’s t test vs. medium (lower right panel).
doi:10.1371/journal.pone.0003271.g003
Activin A & LC Differentiation
PLoS ONE | www.plosone.org 5 September 2008 | Volume 3 | Issue 9 | e3271TGFb in LC differentiation has been clearly documented by the
observation that TGFb1 null mice are devoid of LC [21]. More
recently, it was shown that the cytokine milieu present at the
inflammatory site may favour LC differentiation through an
alternative pathway [22; 28]. Indeed, in vitro experiments have
shown that IL-15, in cooperation with GM-CSF, induces the
differentiation of monocytes into cells that express LC markers, such
as E-cadherin, CCR6 and Langerin but lacking the expression of
conventional Birbeck granules [22]. The present study adds Activin
A to the limited list of cytokines that possess the potential to promote
LC differentiation. Activin A is a member of the TGFb family and
shares some of the intra-cellular signalling pathways with this
cytokine [48]. However, the ability to induce LC differentiation is
not a general feature shared by allTGFb family member proteins,as
documented by the lack of activity of BMP-6 inour assay conditions.
The selective action of Activin A versus BMP-6 is likely to be due to
the usage of specific transmembrane receptors and the activation of
different signalling pathways [49; 50].
LC form a cellular network in the epidermis that constitutes the
first immunological barrier against pathogens and dangerous insults.
Following antigen capture, LC leave the epidermis by a mechanism
that depends on the expression of chemotactic receptors, adhesion
molecules and proteases [10; 14; 51]. Emigrating skin cells enter
lymphatic vessels located in the superficial dermis to finally reach
draining lymph nodes where they present processed antigens to
naı ¨ve T cells [52]. During this migratory process, LC acquire a
mature phenotype that is associated with the expression of homing
receptors, co-stimulatory molecules and the ability to release several
cytokines [10; 52; 53]. The results presented in this study show that
LC generated in the presence of Activin A are fully competent to
undergo a maturation process, as evaluated by the expression of
CCR7 and the downregulation of CCR6, the expression of CD80
and CD83, the ability to induce T cell proliferation and to secrete
high levels of chemokines (i.e. CCL20 and CCL22) and cytokines
(TNF-a, IL-12p70).
LC are normally confined to the basal and suprabasal layer of
the epidermis and stratified epithelia of mucosal surfaces. These
cells are clearly distinct from dermal/interstitial DC which lack
Birbeck granules and Langerin expression, but express DC-SIGN,
Factor XIIIa and more rarely CD1a [54–58]. The current view
proposes that under steady-state conditions, dermal-resident
CD14
+ precursor cells have the potential to migrate to the
epidermis in response to CCL20 and there, in the presence of
keratinocyte-derived TGFb, differentiate into immature resident
LC characterized by a weak T cell stimulatory activity. In the
presence of the cytokine rich milieu that characterizes many
pathological conditions, migratory CD14
+ cells further differenti-
ate into more mature LC which possess a higher antigen
presenting activity [25; 26; 28]. In order to evaluate the potential
of skin resident precursor cells to differentiate into LC in response
to Activin A, we performed experiments in which skin biopsies
were inoculated ex-vivo with Activin A and further incubated in
vitro [46]. The immunohistochemical evaluation of these skin
explants clearly show that the injection of Activin A induced a
strong increase in the number of Langerin
+/CD1a
+ cells in both
the epidermal and dermal compartments in a time-dependent
manner. Due to the experimental conditions employed, Langerin
+
Figure 4. Activin A induces Langerhans cells differentiation in
epidermis-depleted skin explants. Langerin expression was eval-
uated in the dermal layer, separated from skin explants by dispase
digestion and subsequently treated for 72 hrs after i.d. injection with
100 ng Activin A (magnification 100X, inset 400X.).
doi:10.1371/journal.pone.0003271.g004
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Further we show that Langerin
+ cells can be induced to
differentiate by Activin A within the dermis in the absence of
epidermis. In agreement with these results, cells emigrated from
skin explants could also be induced to differentiate into Langerin
+/
CD1a
+ cells by the presence of Activin A in vitro. These findings
are compatible with the description of CD14
+, Langerin
+ LC
precursors located in the superficial and deep dermis, predomi-
nantly in perivascular areas [24; 26]. Although the precise
characterization of Activin A-responsive dermal LC precursors is
beyond the aim of the present study, these results clearly document
that Activin A can induce the local differentiation of dermal LC
precursors. In this contest it is interesting to note that Stoitzner et
al. reported that in mice overexpressing in the follistatin, the
natural Activin A antagonist, the number of LC is reduced [45].
Although Activin A is very weakly expressed in normal skin, its
expression was dramatically increased in lichen planus biopsies. In
this condition, Activin A was expressed both in the superficial
epidermis and in the dermis by stromal cells, infiltrating
leukocytes, including mast cells and some blood vessels. As
expected on the basis of previous work [29–32], lichen planus
biopsies show a prominent increase in the number of LC which
were present in the deep and superficial derma and in the
epidermis. Of note, LC were often present in clusters localized
around Factor VIII
+ blood vessels, suggesting the involvement of
newly vascular-recruited precursor cells. Although these data
generated in a human disease do not allow formal conclusions, it is
tempting to speculate that during certain pathological conditions
characterized by the local expression of Activin A and inflamma-
tory cytokines (such as GM-CSF and IL-4), dermal LC precursors,
Figure 5. Dermal accumulation of Langerhans cells in lichen planus is associated to abundant production of Activin A. Sections from
normal skin (NS) (a and d) and lichen planus (LP) (b, c, e, f) biopsies were stained for Langerin (a–c) and Activin A (d–f). In normal skin, Langerin
+ cells
are regularly distributed in basal and suprabasal layers and show multiple fine dendrites; no positive cells are detectable in the dermis (panel a). In LP
biopsies, in addition to intraepidermal LC, accumulation of Langerin
+ cells is observed in the dermis within the dense monuclear cell infiltrate (panel
b). At high power view, Langerin
+ cells show an ovoidal/dendritic shape (panel c) and are found surrounding Factor VIII
+ dermal blood vessels (arrow
head, inset in c). Serial sections from the same tissue blocks were stained for Activin A. Normal skin (panel d) showed weak intraepithelial reactivity
(red arrow head); in the dermis, mast cells and occasional spindle cells were positive for Activin A (black arrow heads). In LP, Activin A was strongly
induced in the superficial layers of epidermis; in the dermis, a diffuse reactivity can be observed in numerous cells within the inflammatory infiltrate
(panel e). This cell population includes endothelial cells and a mixture of non-lymphoid mononuclear cells (panel f). Magnification 100x (a, b, d, e; scale
bar 200 micron) and 400x (c, f; scale bar 50 micron).
doi:10.1371/journal.pone.0003271.g005
Activin A & LC Differentiation
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to LC within the stromal compartment. This model may help to
explain the origin of LC localized in the deep dermal layers, away
from the epidermis and from superficial lymphatic vessels.
Lichen planus is an autoimmune disease characterized by a
prominent cellular infiltrate mainly composed of DC, LC,
cytotoxic T lymphocytes and NK cells, localized in close proximity
of apoptotic keratinocytes [29–32]. The involvement of the TGFb
family members in this pathology is suggested by several
observations. First, BMP-4 is upregulated in the epithelium of
lichen planus [59]. Second, several lines of evidence suggest that
the TGFb activation and/or signal transduction pathway might be
defective in this disease. Indeed, lichen planus is associated with
epithelial hyperproliferation, a situation that is usually negatively
controlled by TGFb, and this is consistent with the identification
of TGFb positive T cells in the sub-epithelial lymphocytic infiltrate
but not within the epithelium itself. It is therefore of interest to
note that this defective TGFb pathway is associated with a high
expression of Activin A (this study). In this context it is likely that
Activin A may have a prominent role in LC differentiation in
lichen planus. Furthermore, Activin A may contribute to the
pathogenesis of lichen planus by favouring epithelial hyperplasia.
In summary, this study presents a new model in which Activin A
induces the differentiation of circulating CD14
+ cells into LC.
Since Activin A is abundantly produced during certain inflam-
matory conditions, we propose that this cytokine represents a new
pathway, alternative to TGFb, responsible for LC differentiation
during inflammatory/autoimmune conditions.
Materials and Methods
The study was conducted in accordance with a protocol
approved by the Spedali Civili of Brescia Institutional Ethical
Board (Brescia, Italy) and the Board of the CTO Hospital (Turin,
Italy); written informed consent was obtained from all patients.
Cell cultures
CD14
+ monocytes were isolated from buffy coats (Centro
Trasfusionale Brescia, Italy) by positive magnetic separation using
CD14 immunomagnetic beads (Miltenyi Biotec, Auburn, CA) [60].
To generate LC, monocytes were cultured for 6 days in 6 wells tissue
culture plates (Costar, Corning, Cambridge, MA) in 10% heat-
inactivated FCS RPMI 1640 (Sigma, St. Louis, MO) supplemented
with 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-
glutamine. GM-CSF 100ng/ml and IL-4 10 ng/ml were added at
day 0. 10ng/ml TGFb1 or 100 ng/ml Activin A were also added at
day 0. All cytokines were from Peprotech, Rocky Hill, NJ. Half the
culture medium was replaced with fresh medium containing
cytokines on day 2 and 4. LC maturation was induced by incubation
with CD40L-transfected J558 cells (1:4 ratio) for 24 hrs.
Flow cytometric analysis
Surface phenotype analysis was performed using the following
antibodies: phycoerythrin (PE)-conjugated anti-CD1a (anti-CD1a-
PE), anti-Langerin (CD207)-PE, anti-E-cadherin, and anti-CD83-
PE (Immunotech, Marseille, France); anti-human leukocyte
antigen (HLA)-ABC-PE and FITC-conjugated anti-CD1a (anti-
CD1a-FITC; Dako, Glostrup, Denmark); anti-HLA-DR-PE, anti-
CD80-PE, (BD PharMingen, San Diego, CA); anti-CD86-PE,
anti-CD14-PE, anti-CC chemokine receptor 7 (CCR7)-PE, and
anti-CCR6-FITC (R&D Systems). Anti-CLA-FITC rat mAb (BD
PharMingen) was also used. Mouse immunoglobulin G1 (IgG1)-
PE, mouse IgG1-FITC, rat anti-mouse IgG1-FITC, and rat
IgG2a-PE were from BD Pharmingen. Purified mouse IgG1 (R&D
Systems), rat IgM-FITC, mouse IgG2b-PE, mouse IgG2a-PE (BD
PharMingen), or mouse IgG2b-FITC (Beckman Coulter, Hialeah,
FL) were used as an isotype control. Cells were analyzed with a
FACScan flow cytometer (Becton Dickinson, San Jose, CA) using
CellQuest software.
Transmission electron microscopy
10
6 cells were fixed with 2.5% glutaraldehyde in 0.1 M
cacodylate buffer (pH 7.4) and postfixed with 1% osmium
tetroxide in 0.1 M cacodylate buffer (pH 7.4). Next, cells were
dehydrated through a graded series of ethanol and embedded in
araldite (Poersch, Frankfurt, Germany). Ultrathin sections were
counterstained with uranyl acetate and lead citrate and were
examined with a Zeiss electron microscope (EM 906, Zeiss,
Oberkochen, Germany).
Evaluation of DC functions
Irradiated immature and CD40L-stimulated LC were added in
triplicate in graded doses to 2610
5 purified allogeneic T cells in
96-well round-bottom plates. [
3H]Thymidine incorporation was
measured on day 5 after a 16-h pulse (5 Ci/mmol; Amersham
Biosciences, Freiburg, Germany). Human IL-12p70, Activin A,
TGFb1, MDC/CCL22, TARC/CCL17, MIP-3a/CCL20 pro-
tein levels in the culture supernatants were measured by sandwich
ELISA (R&D Systems, Minneapolis, MN). DC migration was
evaluated using a 48-well microchemotaxis chamber (Neuroprobe,
Pleasanton, CA) with 5-mm pore size polyvinylpyrrolidone
polycarbonate filters (Neuroprobe) as previously described [61].
RNA purification and real time RT-PCR analysis
RNA samples, extracted by using TRIzol (Invitrogen, Carlsbad,
CA), were treated with DNase (Invitrogen) and single-stranded
complementary DNA (cDNA) was synthesized by reverse
transcription of 2 mg total RNA using random hexamers and the
Superscript First-Strand Synthesis System for RT-PCR (Invitro-
gen). The cDNAs were then amplified in duplicate by real-time
PCR using the Platinum SYBR Green (Invitrogen) in a final
volume of 25 ml and quantitative analysis was carried out as
previously described [47]. The sequences of primers were as
follows: Activin A (sense 59-GCA GAA ATG AAT GAA CTT
ATG GA-39; antisense 59-GTC TTC CTG GCT GTT CCT
GAC T-39), TGFb1 (sense 59-GCG TGC TAA TGG TGG AAA-
39; antisense 59-CGG TGA CAT CAA AGA TAA CCA C-39), b-
actin (sense, 59-GTT GCT ATC CAG GCT GTG-39; antisense,
59-TGT CCA CGT CAC ACT TCA-39).
Skin explant cultures
Skin specimens were obtained from patients undergoing
corrective breast or abdominal plastic surgery. Cytokines were
injected into the dermis with a MicroFine insulin syringe (29 gauge
needle) in the indicated amounts and in a total volume of 20 ml. At
the site of injection, a ,5-mm wheal appeared and a 6 mm punch
biopsy was taken. For immunohistochemistry, skin biopsies were
cultured at air-medium interface with the epidermis side up in a
six-well culture plate (Costar) on sterilized stainless steel grids
covered with a filter (Millipore, Bedford, MA; 45 mm), at 37u Ci n
5% CO2 humidified air [46; 62]. At the indicated times, the
explants were harvested, snap frozen, and stored in liquid
nitrogen. To study phenotypic development of epidermal and
dermal DC separately, the epidermal and dermal layers were
separated by dispase digestion for 1 h at 37uC (Dispase grade II,
50mg/ml; Roche). To obtain emigrated skin cells, the epidermal
and dermal layers were placed directly in 1 ml culture medium
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with 100 ng/ml Activin A. After 7 h, migratory cells were
collected, counted in hemocytometers using trypan blue exclusion
and cultured in the presence of GM-CSF and Activin A for 6 days.
Tissue specimens and staining procedures
Paraffin embedded tissue blocks were taken from the archive of
the Department of Pathology of the University of Brescia/Spedali
Civili di Brescia; tissues included normal skin, oral (13 cases) and
cutaneous (21 cases) lichen planus and granulosa cell tumors (3
cases). Four micron tissue sections were used for immunohisto-
chemical staining using primary Abs to the following antigens:
human Activin A (clone E4, dilution 1:50, Serotec, Oxford, UK),
human Langerin (clone 12D6, 1:200, Vector Laboratories,
Burlingame, CA), human Factor VIII-related antigen (rabbit
polyclonal, 1:100, Neomarkers, Westnghouse, CA). Upon antigen
retrieval with microwave treatment (3 cycles of 5 min6750 W) or
thermostatic bath (409 at 89u) in EDTA buffer solution, reactivity
was revealed using Real EnVision Mouse/Rabbit-HRP (Dako-
Cytomation, Glostrup, Denmark) or SuperSensitive IHC Detec-
tion System (BioGenex, San Ramon, CA). For double-immuno-
fluorescence staining anti-human Langerin and Factor VIII-
related antigen were revealed respectively using a goat anti-mouse
IgG2b (1:75, Southern Biotek, Birmingham, AL) followed by
Streptavidin Texas Red (1:75, Southern Biotek) and a FITC-
conjugated swine anti-rabbit (1:30, Dako Cytomation). For
immunohistochemical staining of Activin A, positive tissue control
was represented by granulosa cell tumors that strongly expressed
this protein [63]; no reactivity was observed when omission of
primary Ab and irrelevant isotype matched primary antibody were
used. Immunostained sections were independently examined by
two pathologists (WV and FF); digital images taken using the
Olympus BX60 microscope and a DP-70 Olympus digital camera
were processed using Analysis Image Processing software.
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